Welcome to our dedicated page for Navidea Biopharm news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharm stock.
Navidea Biopharm (NAVB) is a leader in developing precision diagnostic tools and targeted immunotherapies through its patented manocept platform. This page provides authorized updates on clinical advancements, regulatory developments, and strategic initiatives central to its mission of improving disease detection and treatment.
Investors and medical professionals will find verified updates on NAVB's CD206-targeting technologies, including SPECT/PET imaging agents and macrophage-focused therapies. Our curated news collection covers essential developments while maintaining compliance with financial disclosure standards.
Key content includes updates on clinical trial progress, FDA communications, partnership announcements, and peer-reviewed research findings. All materials are sourced from official company releases and accredited industry publications to ensure reliability.
Bookmark this page for streamlined access to NAVB's latest developments in precision immunodiagnostics and therapeutic delivery systems. Check regularly for updates on innovations leveraging the company's expertise in macrophage biology and targeted radiopharmaceuticals.
Navidea Biopharmaceuticals (NAVB) has announced the extension of its Section 382 Rights Agreement from April 6, 2025, to April 7, 2027. This strategic move aims to protect approximately $170 million in U.S. federal NOLs and $9 million in R&D tax credits that could offset future taxable income.
The Rights Plan prevents an 'ownership change' under Section 382 of the Internal Revenue Code by discouraging any person or group from acquiring 4.99% or more of Navidea's outstanding common stock. If triggered, existing shareholders can purchase shares at a 50% discount or receive five shares for each right, excluding the acquiring party.
The company originally implemented this plan on April 7, 2022, declaring one preferred share purchase right per common stock outstanding as of April 12, 2022. The Board maintains discretion to grant exemptions to this plan.
Navidea Biopharmaceuticals, a company specializing in precision immunodiagnostic agents and immunotherapeutics, announced the disappointing results of an exploratory analysis for their NAV3-33 clinical trial. This trial aimed to evaluate the efficacy of Tc 99m tilmanocept imaging in predicting early responses to anti-TNFα therapy for rheumatoid arthritis (RA). The analysis, completed on July 2, 2024, showed that while the imaging technique could reliably target macrophage activity, it failed to accurately predict treatment responses, with accuracy consistently below 70%, far from the anticipated 90%. Consequently, Navidea will suspend activities related to this RA trial and shift focus to other therapeutic assets.
Navidea Biopharmaceuticals announced a virtual special meeting of stockholders on July 8, 2024, to vote on two proposals. The first proposal is an amendment to the company's certificate of incorporation to allow stockholders to act by written consent. The second proposal is to implement a reverse stock split of the company's common stock at a ratio of up to 1-for-50,000 shares. The final decision regarding the reverse stock split will be determined by the Board of Directors. Navidea's CFO, Craig A. Dais, highlighted the importance of these measures in pursuing strategic partnerships and reducing costs. Additionally, three directors resigned from the board, and the company terminated its executive consulting agreement with G2G Ventures.
